Replies to post #113804 on Biotech Values

[DewDiligence]

2010 worldwide in-market sales of Tysabri were $1.2B, +16% YoY (http://sec.gov/Archives/edgar/data/875045/000095012311007759/b84664exv99.htm ).

Results of the iHub survey on this matter (from 1/13/10) can be found at http://investorshub.advfn.com/boards/board_survey_results.asp?board_id=1418&Survey_Num=129 .

[genisi]

From Biogen's CC:

Worldwide, net patient additions averaged 133 per week, down from 162 during the third quarter. This drop in patient addition is something we are watching but nothing that we are overly concerned about.

http://seekingalpha.com/article/250094-biogen-idec-ceo-discusses-q4-2010-earnings-call-transcript

Price increases helped with sales.